BlossomHill Therapeutics
$184.2M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
BlossomHill Therapeutics is currently valued at $413.1M as of December 10, 2025. The company has raised a total of $257.1M in funding.
Capital Efficiency
With a capital efficiency ratio of 1.61x, BlossomHill Therapeutics has achieved a valuation that is 1.61 times the total capital raised. This metric indicates room for improvement in capital deployment.
Investment Perspective
BlossomHill Therapeutics's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is BlossomHill Therapeutics Worth in 2025?
As of 2025, BlossomHill Therapeutics is valued at $413.1M, based on the company's Later Stage VC funding round in December 10, 2025. This valuation positions BlossomHill Therapeutics as one of the leading private companies in the sector.
BlossomHill Therapeutics Valuation History
BlossomHill Therapeutics's funding history demonstrates steady growth and investor confidence.
How BlossomHill Therapeutics Valuation is Determined
Private company valuations like BlossomHill Therapeutics's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
BlossomHill Therapeutics Valuation FAQs
Is BlossomHill Therapeutics profitable?
BlossomHill Therapeutics has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does BlossomHill Therapeutics's valuation compare to competitors?
BlossomHill Therapeutics is valued at $413.1M, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will BlossomHill Therapeutics IPO?
BlossomHill Therapeutics has not announced plans for an initial public offering. Until an IPO, investors can access BlossomHill Therapeutics shares through secondary market platforms.